Shandong Lukang Pharmaceutical Co.Ltd(600789) : Shandong Lukang Pharmaceutical Co.Ltd(600789) announcement on the reply to the notification letter on the preparation for the meeting of the issuance and Examination Committee of allotment and public offering of securities

Securities code: Shandong Lukang Pharmaceutical Co.Ltd(600789) securities abbreviation: Shandong Lukang Pharmaceutical Co.Ltd(600789) Announcement No.: 2022017 Shandong Lukang Pharmaceutical Co.Ltd(600789)

Notice on the preparations for the meeting of the issuance and Examination Committee of allotment and public offering of securities

Reply announcement

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.

Shandong Lukang Pharmaceutical Co.Ltd(600789) (hereinafter referred to as “the company”) recently received the letter on making preparations for the meeting of Shandong Shandong Lukang Pharmaceutical Co.Ltd(600789) allotment issuance and Examination Committee (hereinafter referred to as “notification letter”) issued by China Securities Regulatory Commission (hereinafter referred to as “CSRC”).

In accordance with the requirements of the notification letter, the company and relevant intermediaries have carefully studied the issues raised in the notification letter, explained and replied to the relevant issues. For details, see the company’s website on April 13, 2022( http://www.sse.com.cn. )Reply to the letter on “please make preparations for the meeting of Shandong Shandong Lukang Pharmaceutical Co.Ltd(600789) allotment examination committee”. The company will submit reply materials to the CSRC as required.

The public offering of securities by the company in this allotment still needs to be approved by the CSRC, and there is uncertainty about whether it can be approved and the time of final approval. The company will timely perform the obligation of information disclosure in strict accordance with the provisions of relevant laws and regulations according to the review progress of the matter by the CSRC. Please pay attention to investment risks.

It is hereby announced.

Shandong Lukang Pharmaceutical Co.Ltd(600789) board of directors April 13, 2022

- Advertisment -